Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243686 | 0.81 | SLC22A12 (0.36) | SLC22A12FGFR1FGFR4PDE4APDE4B | |
| SCHEMBL13243610 | 0.81 | MKNK2 (0.36) | PRMT5WDR77 | |
| SCHEMBL14697202 | 0.80 | — | — | |
| SCHEMBL4086353 | 0.77 | SLC22A12 (0.42) | SLC22A12FGFR1FGFR4PDE4APDE4B | |
| SCHEMBL24262371 | 0.77 | SLC22A12 (0.40) | SLC22A12FGFR1FGFR4PDE4APDE4B | |
| SCHEMBL29378331 | 0.77 | ENPP3 (0.36) | FGFR1FGFR4 | |
| SCHEMBL306515 | 0.77 | ENPP3 (0.36) | FGFR1FGFR4 | |
| SCHEMBL1187873 | 0.76 | — | — | |
| SCHEMBL16769961 | 0.76 | SLC22A12 (0.41) | SLC22A12FGFR1FGFR4PDE4APDE4B | |
| SCHEMBL12594299 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119306753-A | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-108395433-B | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | INCYTE CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180237442-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2018-08-23 | — | — | US | disclosed |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8410265-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1773836-B1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PROD INC (US) | 2012-09-05 | — | — | EP | disclosed |
| CN-102348693-A | Methods for preparing JAK inhibitors and related intermediate compounds | INCYTE CORP | 2012-02-08 | — | — | CN | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | SLC22A12 4552/4885FGFR1 1535/4885FGFR4 1065/4885 |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | SLC22A12 4862/4885FGFR1 500/4885FGFR4 490/4885 |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SLC22A12 4820/4885FGFR1 567/4885FGFR4 744/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | SLC22A12 4820/4885FGFR1 567/4885FGFR4 744/4885 |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | SLC22A12 828/4885FGFR1 12/4885FGFR4 68/4885 |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | JAK1, JAK3, JAK2 | SLC22A12 4819/4885FGFR1 799/4885FGFR4 612/4885 |
| US-20180237442-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SLC22A12 4820/4885FGFR1 567/4885FGFR4 744/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SLC22A12 4820/4885FGFR1 567/4885FGFR4 744/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SLC22A12 4820/4885FGFR1 567/4885FGFR4 744/4885 |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SLC22A12 4820/4885FGFR1 567/4885FGFR4 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.